Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 871 to 880 of 2588 total matches.

Booster Doses of COVID-19 Vaccines

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
adult (see Table 1).1,2 DOSAGE — The booster dose is the same as the dose for primary immunization ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8 |  Show IntroductionHide Introduction

Exenatide (Byetta) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005  (Issue 1210)
. Glucagon-like peptide-1 (GLP-1) is one of these. Exenatide is a GLP-1 agonist (incretin mimetic ...
Exenatide injection (Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin (Glucophage, and others), a sulfonylurea, such as glyburide (DiaBeta, and others), or both. Exenatide is not indicated for use with insulin.
Med Lett Drugs Ther. 2005 Jun 6;47(1210):45-6 |  Show IntroductionHide Introduction

Rosiglitazone/Glimepiride (Avandaryl) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
(Avandamet). 1 Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
to tetracyclines. Pronunciation Key Omadacycline: oh mad" a sye' kleen Nuzyra: new zye' rah Table 1 ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
(Tymlos) and teriparatide (Forteo) were approved earlier.1 Other drugs used for treatment ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

Drugs for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013  (Issue 1411)
triglyceride levels and should be tried first.1-3 TRIGLYCERIDE LEVELS AND RISK — Mildly (150- 200 mg/dL ...
Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations of triglycerides, but less so than fibrates, niacins or fish oil. Lifestyle changes such as weight reduction, exercise and decreasing alcohol intake can also lower serum triglyceride levels and should be tried first.
Med Lett Drugs Ther. 2013 Mar 4;55(1411):17-9 |  Show IntroductionHide Introduction

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
6.25, 12.5 mg tabs 20, 40 mg tabs 2.5 mg tabs 1, 2.5 mg tabs 5, 10 mg tabs, ODTs Imitrex and generics ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9   doi:10.58347/tml.2023.1678b |  Show IntroductionHide Introduction

Safe Needles

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
SHEATHING MECHANISMS Sliding Sleeve Click Lock ICU Medical (Irvine, CA; 1-800-824-7890) IV catheter ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Med Lett Drugs Ther. 1991 Apr 5;33(841):32 |  Show IntroductionHide Introduction

Lodoxamide for Vernal Keratoconjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 1994  (Issue 918)
, has been marketed in a 0.1% ophthalmic solution (Alomide − Alcon) for treatment of vernal keratoconjunctivitis ...
Lodoxamide, a mast cell stabilizer, has been marketed in a 0.1% ophthalmic solution (Alomide - Alcon) for treatment of vernal keratoconjunctivitis.
Med Lett Drugs Ther. 1994 Mar 18;36(918):26 |  Show IntroductionHide Introduction

Rivaroxaban (Xarelto) for Acute Coronary Syndrome

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
discharge.1 The addition of the oral anticoagulant warfarin (Coumadin, and others) to dual antiplatelet ...
The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy with aspirin and clopidogrel (Plavix) or another thienopyridine, plus a parenteral anticoagulant while the patient is hospitalized, followed by antiplatelet therapy alone after discharge. The addition of the oral anticoagulant warfarin (Coumadin, and others) to dual antiplatelet therapy is generally not recommended for this indication because of fluctuations in its anticoagulant effect and the risk of bleeding. A recently published trial found that addition of...
Med Lett Drugs Ther. 2011 Dec 12;53(1379):97 |  Show IntroductionHide Introduction